

Intraarticular Application of Opioids versus Glucocorticoids versus Placebo in Gonarthrosis

Submission date 24/08/2005	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 21/10/2005	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 06/02/2008	Condition category Musculoskeletal Diseases	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Joachim Sieper

Contact details
Charité Campus Benjamin Franklin
Dept of Rheumatology
Hindenburgdamm 30
Berlin
Germany
12200
+49 (0)3084454414
joachim.sieper@charite.de

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
N/A

Study information

Scientific Title

Study objectives

Assessment of efficacy and safety of intraarticular applicated Morphine versus Dexamethasone versus Placebo in gonarthrititis in inflammatory rheumatic disease

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Gonarthrititis in inflammatory rheumatic disease

Interventions

Single injection of Morphine 3 mg or Dexamethasone 4 mg or Placebo during needle arthroscopy. Reearthroscopy after 7 days.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Morphine, Dexamethasone

Primary outcome measure

Improvement of VAS pain of at least 20 mm on a 0-100 scale.

Secondary outcome measures

Improvement of a numeric pain scale, sleep quality, global daily activity, knee mobility with Lysholm and Gilquist Score, Western Ontario McMaster Universities Osteoarthritis (WOMAC) index, relief of pain on a numeric scale from 0-3.

Overall study start date

01/01/2004

Completion date

01/01/2006

Eligibility**Key inclusion criteria**

1. Age 19-70
2. Gonarthrosis with sonographically evident effusion in inflammatory rheumatic disease
3. Visual analogue score (VAS) pain >30 mm
4. Body weight 50-90 kg
5. Written informed consent

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

60

Key exclusion criteria

1. Pregnancy, lactation
2. Severe or opportunistic infection, infection of the knee
3. Malignant diseases
4. Any other severe diseases
5. Platelets <100/nl, Quick <50
6. Significant findings during clinical examination
7. Participation in a clinical trial within 30 days before inclusion
8. Abuse of hard drugs, benzodiazepines, analgesics, alcohol
9. Therapy with anticoagulants

Date of first enrolment

01/01/2004

Date of final enrolment

01/01/2006

Locations

Countries of recruitment

Germany

Study participating centre

Charité Campus Benjamin Franklin

Berlin

Germany

12200

Sponsor information

Organisation

Charité - University Medicine Berlin (Charité - Universitätsmedizin Berlin) (Germany)

Sponsor details

Benjamin Franklin Campus

Department of Rheumatology

Hindenburgdamm 30

Berlin

Germany

12200

+49 (0)3084454414

joachim.sieper@charite.de

Sponsor type

University/education

Website

<http://www.charite.de>

ROR

<https://ror.org/001w7jn25>

Funder(s)

Funder type

Research organisation

Funder Name

German Research Foundation (Deutsche Forschungsgemeinschaft) KFO 100

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration